Buprenorphine Sublingual C Iii + Ketoconazole Interaction
Unknowninteraction on record
Description
ketoconazole), protease inhibitors (e.g., ritonavir) CYP3A4 Inducers Clinical Impact: The concomitant use of buprenorphine and CYP3A4 inducers can decrease the plasma concentration of buprenorphine [see Clinical Pharmacology (12.3)], potentially resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to buprenorphine.
Source: FDA drug label - buprenorphine sublingual c-iii